TRINETRA › Sectors › Healthcare
Alkem Laboratories Limited (ALKEM) — share price, P/E and fundamentals
Alkem Laboratories Limited (NSE: ALKEM) closed at ₹5,113.50 on 30 Oct 2026, -8.4% over one year, against a 52-week range of ₹4,811.00 – ₹5,933.50.
In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹3,740 cr and net profit of ₹520 cr, a 13.9% net margin; revenue grew 10.9% and profit grew 0.1% year on year.
On four consecutive filed quarters its trailing P/E is 28.3; since 27 Jun 2025 its own P/E has ranged from 25.9 to 32.5 (median 29.1), and today's reading is higher than 37% of those 330 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 15.1%, ROCE 20.4%, debt-to-equity 0.12, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 56% of 63 sector peers; PBT margin higher than 59% of 63 sector peers; ROE higher than 57% of 63 sector peers.
Key figures
| Last close | ₹5,113.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -4.0% / -2.3% / -8.4% |
| 52-week low – high | ₹4,811.00 – ₹5,933.50 |
| Market capitalisation | ₹61,132 cr |
| Trailing P/E | 28.3 |
| Price / book | 4.42 |
| EV / EBITDA | 18.2 |
| Earnings yield | 3.5% |
| TTM EPS | ₹180.47 |
| TTM net profit | ₹2,158 cr |
| Quarter revenue | ₹3,740 cr |
| Quarter net profit | ₹520 cr |
| Net margin | 13.9% |
| Revenue growth (YoY) | +10.9% |
| Profit growth (YoY) | +0.1% |
| Return on equity | 15.1% |
| ROCE | 20.4% |
| Debt / equity | 0.12 |
| Current ratio | 2.55 |
| Free cash flow | ₹1,346 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹54.9 cr |
Against Healthcare peers
| Metric | ALKEM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 13.90 | 12.67 | 56 |
| PBT margin | 20.64 | 17.57 | 59 |
| ROE | 15.05 | 13.86 | 57 |
| ROCE | 20.35 | 16.59 | 68 |
| Debt / equity | 0.12 | 0.11 | 53 |
| Cash conversion | 0.83 | 1.25 | 21 |
| Trailing P/E | 28.33 | 43.26 | 20 |
| P/B | 4.42 | 6.02 | 33 |
Questions
What is the P/E ratio of Alkem Laboratories Limited?
Alkem Laboratories Limited's trailing P/E is 28.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 27 Jun 2025 its P/E has ranged 25.9–32.5.
What were Alkem Laboratories Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Alkem Laboratories Limited reported revenue of ₹3,740 cr and net profit of ₹520 cr (consolidated), filed with the exchange on 14 Aug 2026.
What is Alkem Laboratories Limited's ROE?
Return on equity is 15.1% based on the balance sheet dated 31 Mar 2026.
Does Alkem Laboratories Limited have debt?
Debt-to-equity is 0.12 on the balance sheet dated 31 Mar 2026.
What is ALKEM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ALKEM traded between ₹4,811.00 and ₹5,933.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.